Samuel D. Riccitelli
Chairman and interim President and Chief Executive Officer
Mr. Riccitelli is the Chairman and interim President and Chief Executive Officer of Biocept since February 2022. Mr. Riccitelli has been a member of the Board of Directors of Biocept since October 2020 and Chairman of the Board since July 2021. Mr. Riccitelli has served as a member of the Board of Directors of Orthopediatrics, Inc. (Nasdaq: KIDS) since 2017, a company focused exclusively on the orthopedic implant needs of children. He also served as Chief Executive Officer of Pathnostics, LLC, a molecular diagnostics company focused on improving antibiotic stewardship, from 2019 to 2020. From 2017 to 2019, Mr. Riccitelli served as Chairman of the Board of Directors of Precipio, Inc. (Nasdaq: PRPO), a diagnostic services company. From 2012 to 2017, Mr. Riccitelli served as President and Chief Executive Officer and a Director of Signal Genetics, Inc., a publicly traded molecular diagnostic company that was ultimately sold to Miragen Therapeutics, Inc. Mr. Riccitelli was also previously the Executive Vice President and Chief Operating Officer of Genoptix, Inc., a publicly traded diagnostic company that was sold to Novartis in 2011. Mr. Riccitelli served in a number of R&D and general management leadership positions for Becton, Dickinson and Company, as a vice president and general manager and as a board member for BD Ventures, LLC., a venture capital fund. Mr. Riccitelli received a B.A. from Washington and Jefferson College and a M.S. Engineering degree from The University of Texas.
M. Faye Wilson, CPA, MBA
Lead Independent Director
Ms. Wilson is the chair of Biocept’s audit committee. She has been Principal and President of Wilson Boyles & Co., LLC, a business management and strategic planning consulting firm, since 2003. Ms. Wilson also currently serves on the Board of Directors for IQHQ, a real estate investment trust, as well as Sharp Health Care Systems. She has served on the Board of Directors of Biomed Realty Trust, Inc., Farmers Insurance Group of Companies and The Home Depot, Inc. Ms. Wilson was also a senior officer of Home Depot from 1998 through 2002. From 1992 until 1998, Ms. Wilson served in several senior management roles at Bank of America Corporation including Chairman of Security Pacific Financial Services and Executive Vice President of Bank of America.
Marsha A. Chandler Ph.D.
Dr. Chandler is the chair of Biocept’s nominating and governance committee. She was the Executive Vice President/Chief Operating Officer of the Salk Institute for Biological Studies since 2007 where she managed approximately 1,000 scientific and administrative personnel, and oversaw all institutional fiscal, administrative and fund-raising activities. From 1997 to 2007 she served as Senior Vice Chancellor for Academic Affairs at the University of California, San Diego, where she was the chief academic officer responsible for the policies and decisions relating to all academic programs and faculty appointments and performance.
Bruce E. Gerhardt, CPA
Mr. Gerhardt is the chair of Biocept’s compensation committee. He has been self-employed, practicing as a Certified Public Accountant, since 1986. He is also a tax and business advisor providing tax compliance for small businesses and upper income individuals. Gerhardt earned his Bachelor of Arts Degree from the University of Southern California in 1973 and is a member of the American Institute of Certified Public Accountants.
Director and interim Chief Financial Officer
Mr. Morales is the interim Chief Financial Officer of Biocept and board member, bringing more than 30 years of broad leadership experience in the US and Latin America. He has served in multiple senior management or consulting roles with various Fortune 100 companies including Citibank, Bank of America, Arthur Andersen, Mazda North America, and McDonald’s. Mr. Morales led the expansion of Citibank’s consumer finance operation into Latin America and most recently served as president and CEO of Apoyo Financiero, Inc. a Community Development Financial Institution (CDFI). Morales has led multiple private equity backed start-up companies. He earned his Bachelor of Science degree in Finance from the University of Southern California and is a licensed CPA.
Ivor Royston M.D.
Dr. Royston is the chair of Biocept’s science and technology committee. He has served as President, Chief Executive Officer, and Director of Viracta since 2015. From 1990 to 2017, Dr. Royston was a Managing Partner of Forward Ventures, a life science venture capital firm. From 1990 to 2000, Dr. Royston also held the position of Chief Executive Officer of the Sidney Kimmel Cancer Center. Prior to that, Dr. Royston was the Director of Clinical Immunology at University of California, San Diego Cancer Center. Dr. Royston was the co-founder of Hybritech, Inc., which developed the PSA test for prostate cancer; and the co-founder of IDEC Corporation, which developed Rituxan, the first approved monoclonal antibody therapy for lymphoma, and which subsequently merged with Biogen to form Biogen Idec, now Biogen. Dr. Royston received his B.A. and M.D. degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University.
Ms. Rubinstein is CFO of Adverum Biotechnologies and consulting CFO of Medikine, and has been a partner at FLG Partners since 2010. She has over 35 years of operational, financial and capital markets experience and has been CFO of numerous public and private companies. While at FLG, Ms. Rubinstein has served as the permanent or interim CFO of Alector, Apexigen, ArmaGen, Five Prime, Ingenuity, iPierian, Kezar, PaxVax, Retrotope, Sublimity, True North and Tunitas, among others. Ms. Rubinstein also has held various positions at life science companies and investment banks, including Solexa, a public genetic analysis instrumentation company, ChemoCentryx, a biotechnology company, RDJ Advisors, a financial and strategic consulting firm, and Lehman Brothers. Ms. Rubinstein received her M.A. and B.A. degrees in Economics from the University of California, Los Angeles.
Quyen Dao-Haddock, CPA
Ms. Dao-Haddock serves as a member of Biocept’s audit committee. She is a certified public accountant (CPA) with more than 20 years of financial and accounting experience including overseeing technical accounting, budgeting, forecasting, financial modeling, cash management, and SEC reporting. Ms. Dao-Haddock is currently the Controller of IQHQ, Inc., a $2.5 billion start-up real estate investment trust (REIT) focused on the life sciences industry, and a member of the Audit and Compliance committee of Sharp Healthcare.
Ms. Dao-Haddock was previously Chief Accounting Officer of Presidio Property Trust, Inc., where she was responsible for all financial and accounting operations of this REIT with more than $30 million in annual revenues and $200 million in assets. Earlier she was Corporate Controller of American Assets Trust, Inc., an NYSE-listed REIT with more than $315 million in annual revenues and $2 billion in assets, and Controller at Pacific Corporate Group, LLC, a private equity firm with $30 million in revenue and $16 billion in assets. She began her career as an Audit Manager at KPMG LLP, and received a BS in Business Administration, Accounting from San Diego State University.